

Alex C Spyropoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3916166/publications.pdf>

Version: 2024-02-01

161
papers

17,411
citations

44069

48
h-index

13771

129
g-index

163
all docs

163
docs citations

163
times ranked

17315
citing authors

#	ARTICLE	IF	CITATIONS
1	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	3.8	17
2	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 532-535.	3.8	7
3	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , 2022, 399, 118-119.	13.7	25
4	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16.	2.2	9
5	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 209, 94-98.	1.7	34
6	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 50-59.	13.7	172
7	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1279-1287.	3.4	11
8	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. <i>Circulation</i> , 2022, 145, 1471-1479.	1.6	6
9	Comparison of Guidelines for Evaluation of Suspected Pulmonary Embolism in Pregnancy. <i>Chest</i> , 2022, 161, 1628-1641.	0.8	2
10	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2022, 11, e025342.	3.7	0
11	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
12	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. <i>TH Open</i> , 2022, 06, e177-e183.	1.4	1
13	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	3.8	23
14	Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. <i>Expert Review of Hematology</i> , 2022, 15, 597-605.	2.2	6
15	Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 12-16.	2.1	2
16	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336.	1.6	16
17	Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1043-1053.	3.4	55
18	Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 308-315.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 296-300.	2.3	34
20	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association, 2021, 10, e019459.	3.7	30
21	Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 897-901.	2.1	39
22	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thrombosis and Haemostasis, 2021, 121, 1684-1695.	3.4	7
23	Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19. TH Open, 2021, 05, e211-e219.	1.4	8
24	Sex-Based Differences in COVID-19 Outcomes. Journal of Women's Health, 2021, 30, 492-501.	3.3	17
25	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. American Heart Journal, 2021, 235, 12-23.	2.7	36
26	Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood, 2021, 137, 2838-2847.	1.4	133
27	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12520.	2.3	27
28	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	3.4	21
29	External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 52, 1032-1035.	2.1	21
30	Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12547.	2.3	1
31	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. Journal of Thrombosis and Haemostasis, 2021, 19, 2772-2780.	3.8	4
32	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended Prophylaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. American Heart Journal, 2021, 242, 115-122.	2.7	18
33	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1612.	5.1	326
34	A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 159-167.	2.3	5
35	Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110533.	1.7	2
36	Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Journal of the American Heart Association, 2021, 10, e021579.	3.7	8

#	ARTICLE	IF	CITATIONS
37	The HEP-COVID Trial. Heart International, 2021, 15, 62.	1.4	1
38	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Annals of Emergency Medicine, 2020, 76, 470-485.	0.6	46
39	Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. Journal of Thrombosis and Thrombolysis, 2020, 49, 316-320.	2.1	10
40	Heparin Bridging Therapy for Patients on Chronic Oral Anticoagulants in Periprocedural Settings. Seminars in Thrombosis and Hemostasis, 2020, 46, 026-031.	2.7	8
41	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. Journal of the American Heart Association, 2020, 9, e017316.	3.7	18
42	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. TH Open, 2020, 04, e255-e262.	1.4	2
43	Hospitalized COVID-19 Patients and Venous Thromboembolism. Circulation, 2020, 142, 129-132.	1.6	50
44	The underrecognized prothrombotic vascular disease of COVID-19. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 942-943.	2.3	2
45	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Advances, 2020, 4, 3520-3527.	5.2	38
46	Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962092591.	1.7	4
47	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. Journal of Thrombosis and Haemostasis, 2020, 18, 2958-2967.	3.8	98
48	The management of venous thromboembolism in hospitalized patients with COVID-19. Blood Advances, 2020, 4, 4028-4028.	5.2	14
49	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	3.4	131
50	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood, 2020, 135, 1788-1810.	1.4	73
51	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
52	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 1859-1865.	3.8	547
53	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology, 2020, 75, 3140-3147.	2.8	50
54	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thrombosis and Haemostasis, 2020, 120, 924-936.	3.4	12

#	ARTICLE	IF	CITATIONS
55	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 562-568.	2.3	19
56	Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open, 2020, 04, e59-e65.	1.4	104
57	Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. Lancet Haematology, the, 2020, 7, e247-e258.	4.6	28
58	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thrombosis and Haemostasis, 2020, 120, 515-524.	3.4	16
59	External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. Oncologist, 2020, 25, e1083-e1090.	3.7	19
60	Hospital-based use of thromboprophylaxis in patients with COVID-19. Lancet, The, 2020, 395, e75.	13.7	40
61	Emergence of institutional antithrombotic protocols for coronavirus 2019. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 510-517.	2.3	44
62	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
63	New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. Journal of Clinical Medicine, 2020, 9, 1002.	2.4	12
64	Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. Blood, 2020, 136, 33-34.	1.4	5
65	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant—Reply. JAMA Internal Medicine, 2020, 180, 333.	5.1	0
66	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. TH Open, 2020, 04, e344-e350.	1.4	0
67	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. Journal of Thrombosis and Haemostasis, 2019, 17, 1966-1972.	3.8	70
68	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Internal Medicine, 2019, 179, 1469.	5.1	283
69	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. Thrombosis Research, 2019, 182, 159-166.	1.7	48
70	Quality metrics of warfarin initiation in hospitalized older adults. Journal of Thrombosis and Thrombolysis, 2019, 48, 459-465.	2.1	0
71	Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. Journal of Thrombosis and Thrombolysis, 2019, 48, 570-579.	2.1	3
72	Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. Digestive Diseases and Sciences, 2019, 64, 3256-3262.	2.3	8

#	ARTICLE	IF	CITATIONS
73	Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961985089.	1.7	17
74	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. American Heart Journal, 2019, 212, 113-119.	2.7	70
75	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thrombosis Research, 2019, 184, 58-61.	1.7	14
76	Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988602.	1.7	51
77	External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.. Journal of Clinical Oncology, 2019, 37, e18005-e18005.	1.6	2
78	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 575-582.	1.7	18
79	Extended thromboprophylaxis in the acutely ill medical patient after hospitalization â€“ a paradigm shift in post-discharge thromboprophylaxis. Hospital Practice (1995), 2018, 46, 5-15.	1.0	9
80	Direct oral anticoagulants in the treatment of pulmonary embolism. Current Medical Research and Opinion, 2018, 34, 131-140.	1.9	12
81	Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 2279-2280.	27.0	2
82	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. Seminars in Thrombosis and Hemostasis, 2018, 44, 813-822.	2.7	7
83	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Circulation, 2018, 138, 1402-1411.	1.6	26
84	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	27.0	205
85	Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis. JMIR MHealth and UHealth, 2018, 6, e11090.	3.7	7
86	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASSâ€“Cancer-Associated Thrombosis Study. Oncologist, 2017, 22, 1222-1231.	3.7	167
87	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 532-541.	1.7	10
88	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open, 2017, 01, e56-e65.	1.4	94
89	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thrombosis and Haemostasis, 2017, 117, 2415-2424.	3.4	62
90	New paradigms in venous thromboprophylaxis of medically ill patients. Thrombosis and Haemostasis, 2017, 117, 1662-1670.	3.4	44

#	ARTICLE	IF	CITATIONS
91	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 544-553.	3.4	29
92	European Union-28: An annualised cost-of-illness model for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 800-808.	3.4	85
93	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248.	3.4	64
94	The BRIDGE trial: What the hospitalist should know. <i>Journal of Hospital Medicine</i> , 2016, 11, 652-657.	1.4	4
95	Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. <i>American Journal of Medicine</i> , 2016, 129, 1001.e9-1001.e18.	1.5	69
96	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	5.8	40
97	Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2016, 95, 1457-1464.	1.8	48
98	Perioperative Management of the Direct Oral Anticoagulants. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1073-1084.	2.2	14
99	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , 2016, 34, 19-25.	1.6	3
100	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , 2016, 129, S54-S63.	1.5	9
101	External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 530-536.	3.4	47
102	Cost-of-illness model for venous thromboembolism. <i>Thrombosis Research</i> , 2016, 145, 130-132.	1.7	12
103	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	3.4	201
104	All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2015, 114, 685-694.	3.4	2
105	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	27.0	951
106	Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 113-124.	1.9	12
107	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?. <i>Blood</i> , 2015, 126, 1126-1126.	1.4	1
108	External Validation of a Risk Assessment Model for Bleeding Risk in Medical Patients: Findings from the Improve Investigators in a Tertiary Health System. <i>Blood</i> , 2015, 126, 748-748.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	2.9	81
110	Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2014, 129, 1850-1859.	1.6	234
111	External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System. Journal of the American Heart Association, 2014, 3, e001152.	3.7	107
112	Treatment and Long-Term Management of Venous Thromboembolism. Clinics in Laboratory Medicine, 2014, 34, 519-536.	1.4	3
113	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. Circulation, 2014, 130, 410-418.	1.6	53
114	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
115	Venous Thromboembolism Risk in Patients With Inflammatory Bowel Disease: Defining the Benefits of Pharmacologic Prophylaxis. Clinical Gastroenterology and Hepatology, 2014, 12, 1577.	4.4	1
116	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis, 2014, 112, 692-699.	3.4	67
117	Validating the IMPROVE Venous Thromboembolism (VTE) Risk Score: Retrospective Analysis of Electronic Data From a Large Health System. Chest, 2014, 145, 522A.	0.8	1
118	Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. Blood, 2014, 124, 4271-4271.	1.4	0
119	Practical issues, limitations, and periprocedural management of the NOACs. Journal of Thrombosis and Thrombolysis, 2013, 36, 212-222.	2.1	29
120	Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thrombosis Research, 2013, 132, 520-526.	1.7	45
121	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 2013, 368, 513-523.	27.0	524
122	Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 288-298.	0.9	24
123	Venous thromboembolism management: where do novel anticoagulants fit?. Current Medical Research and Opinion, 2013, 29, 783-790.	1.9	6
124	Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 504-512.	1.7	11
125	Interruption of Warfarin Anticoagulation for Dental Surgery: Response. Chest, 2013, 144, 1424-1426.	0.8	4
126	Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients. , 2013, , 741-745.		0

#	ARTICLE	IF	CITATIONS
127	Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. <i>Circulation</i> , 2012, 126, 1630-1639.	1.6	406
128	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1027-1034.	3.4	25
129	Perioperative Management of Antithrombotic Therapy. <i>Chest</i> , 2012, 141, e326S-e350S.	0.8	1,461
130	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012, 142, 265-266.	0.8	3
131	How I treat anticoagulated patients undergoing an elective procedure or surgery. <i>Blood</i> , 2012, 120, 2954-2962.	1.4	331
132	Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. <i>Thrombosis and Haemostasis</i> , 2012, 108, 291-302.	3.4	137
133	Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery" <i>Thrombosis and Haemostasis</i> , 2012, 108, 213-216.	3.4	25
134	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	3.4	24
135	The use of weighted and scored risk assessment models for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1072-1076.	3.4	40
136	Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. <i>Thrombosis and Haemostasis</i> , 2011, 106, 405-415.	3.4	61
137	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. <i>Chest</i> , 2011, 140, 706-714.	0.8	401
138	The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 196-208.	2.1	18
139	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 407-416.	2.1	105
140	Factors at Admission Associated With Bleeding Risk in Medical Patients. <i>Chest</i> , 2011, 139, 69-79.	0.8	347
141	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. <i>Blood</i> , 2011, 118, 542-542.	1.4	3
142	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , 2011, 118, 545-545.	1.4	1
143	Bridging therapy and oral anticoagulation: current and future prospects. <i>Current Opinion in Hematology</i> , 2010, 17, 444-449.	2.5	28
144	Risk assessment of venous thromboembolism in hospitalized medical patients. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 419-425.	2.6	17

#	ARTICLE	IF	CITATIONS
145	To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. Journal of Thrombosis and Thrombolysis, 2010, 29, 192-198.	2.1	15
146	Rates of venous thromboembolism occurrence in medical patients among the insured population. Thrombosis and Haemostasis, 2009, 102, 951-957.	3.4	57
147	Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. Journal of Thrombosis and Thrombolysis, 2009, 28, 458-464.	2.1	55
148	Use of Emerging Oral Anticoagulants in Clinical Practice. Annals of Surgery, 2009, 250, 219-228.	4.2	30
149	Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (from the Tj ETQq1 1 0.784314 rgBT /Ozlock 10	0.784314	10
150	The Perioperative Management of Antithrombotic Therapy. Chest, 2008, 133, 299S-339S.	0.8	763
151	Epidemiology of Venous Thromboembolism in Cardiorespiratory and Infectious Disease. American Journal of Medicine, 2008, 121, 935-942.	1.5	51
152	Investigational treatments of venous thromboembolism. Expert Opinion on Investigational Drugs, 2007, 16, 431-440.	4.1	36
153	Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. Chest, 2007, 132, 936-945.	0.8	446
154	Management of Venous Thromboembolism in the Elderly. Drugs and Aging, 2006, 23, 651-671.	2.7	28
155	Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Current Medical Research and Opinion, 2006, 22, 1109-1122.	1.9	49
156	Prevention of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2006, 32, 755-766.	2.7	27
157	Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Chest, 2005, 128, 958-969.	0.8	55
158	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 2005, 94, 750-9.	3.4	173
159	Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clinical Therapeutics, 2004, 26, 1149-1159.	2.5	72
160	Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy. Chest, 2004, 125, 1642-1650.	0.8	105
161	Management of Acute Proximal Deep Vein Thrombosis. Chest, 2002, 122, 108-114.	0.8	111